Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90.51 CHF | -0.66% | -2.84% | +6.65% |
05-27 | Novartis: positive phase III results in C3G | CF |
05-27 | Novartis: presented results for kidney disease | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.65% | 204B | |
+39.22% | 727B | |
+30.57% | 592B | |
-7.85% | 347B | |
+15.48% | 319B | |
-0.12% | 274B | |
+12.55% | 238B | |
-6.09% | 203B | |
-3.37% | 160B | |
-2.28% | 120B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- NOVARTIS AG : Goldman Sachs reaffirms its Buy rating